Dexus Convenience Retail REIT

DXC

Dexus Convenience Retail REIT engages in owning and management of portfolio of properties. The company is headquartered in Sydney, New South Wales and currently employs 0 full-time employees. The company went IPO on 2017-07-27. The Fund's portfolio is valued at approximately $781 million, is predominantly located on Australia's eastern seaboard and leased to Australian and international convenience retail tenants. The portfolio has a long weighted average lease expiry and contracted annual rent increases, providing a high level of income security. The Fund has a conservative approach to capital management with a target gearing range of 25-40%. The Fund consists of three registered managed investment schemes domiciled in Australia: Convenience Retail REIT No. 1, Convenience Retail REIT No. 2 and Convenience Retail REIT No. 3. The Fund's manager is Convenience Retail Management Pty Ltd.

Dexus Industria REIT.

DXI

Dexus Industria REIT is an Australian real estate investment trust, which engages in interests in a workspace focused portfolio of several established, industrial, technology park and business park assets. The company is headquartered in Sydney, New South Wales and currently employs 0 full-time employees. The company went IPO on 2013-12-03. The firm's segments include Direct investments and Joint ventures. The company has a target gearing range of 30 - 40%. Its properties include 34 Australis Drive, Derrimut VIC; 80-96 South Park Drive, Dandenong South VIC; 1 West Park Drive, Derrimut VIC; 89 West Park Drive, Derrimut VIC; 140 Sharps Road, Tullamarine VIC; 13 Ricky Way & 10 Jersey Drive, Epping VIC; 81-83 Rushdale Street, Knoxfield VIC; 45-55 O'Briens Road, Corio VIC; 137-147 Fitzgerald Road, Laverton North VIC; 78 Henderson Road, Rowville VIC; 350 & 356 Cooper Street, Epping VIC; 60 Grindle Road, Wacol QLD, and various others. The firm's manager is Dexus Asset Management Limited.

Dimerix Limited

DXB

Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. The company develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The firm is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.